Cyanocobalamin Farmacia: Uses, Dosage & Side Effects
A prescription-strength oral vitamin B12 (cyanocobalamin) supplement for the treatment and prevention of vitamin B12 deficiency, pernicious anemia, and associated neurological conditions
Cyanocobalamin Farmacia is a prescription-strength oral vitamin B12 supplement containing 1 mg (1000 micrograms) of cyanocobalamin per film-coated tablet. It is used to treat and prevent vitamin B12 deficiency, which can lead to megaloblastic anemia, neurological damage including peripheral neuropathy, and cognitive impairment. Cyanocobalamin is the most widely used and studied synthetic form of vitamin B12, listed on the WHO Model List of Essential Medicines. High-dose oral cyanocobalamin has been shown in multiple clinical trials to be as effective as intramuscular injections for most patients with vitamin B12 deficiency, offering a convenient and non-invasive alternative to injectable therapy.
Quick Facts: Cyanocobalamin Farmacia
Key Takeaways
- Cyanocobalamin Farmacia contains 1 mg of vitamin B12 per tablet and is used to treat confirmed vitamin B12 deficiency, including pernicious anemia and deficiency caused by malabsorption, dietary insufficiency, or medication interactions.
- High-dose oral cyanocobalamin (1000 micrograms daily) has been shown in systematic reviews to be as effective as intramuscular B12 injections for correcting vitamin B12 deficiency in most patients, including those with pernicious anemia.
- Vitamin B12 deficiency can cause serious and potentially irreversible neurological damage if left untreated; early diagnosis and treatment are essential to prevent permanent nerve injury and subacute combined degeneration of the spinal cord.
- Cyanocobalamin is generally very well tolerated with minimal side effects; the most important precaution is in patients with Leber hereditary optic neuropathy, where cyanocobalamin is contraindicated due to risk of rapid optic atrophy.
- Regular monitoring of serum B12 levels, complete blood counts, and methylmalonic acid or homocysteine levels is recommended to assess treatment response and guide ongoing therapy duration.
What Is Cyanocobalamin Farmacia and What Is It Used For?
Cyanocobalamin Farmacia contains the active substance cyanocobalamin, which is a synthetic form of vitamin B12 (cobalamin). Vitamin B12 is an essential water-soluble vitamin that the human body cannot produce on its own and must obtain from dietary sources or supplements. In its natural state, vitamin B12 is found almost exclusively in animal-derived foods such as meat, fish, eggs, and dairy products. Cyanocobalamin is the most commonly used and extensively studied pharmaceutical form of vitamin B12, distinguished by the presence of a cyanide group coordinated to the central cobalt atom of the cobalamin molecule.
Once ingested and absorbed, cyanocobalamin is converted within cells to two metabolically active coenzyme forms: methylcobalamin and 5-deoxyadenosylcobalamin (adenosylcobalamin). These coenzymes are essential cofactors for two critical enzymatic reactions in human metabolism. Methylcobalamin serves as a cofactor for the cytoplasmic enzyme methionine synthase, which catalyzes the transfer of a methyl group from 5-methyltetrahydrofolate to homocysteine, producing methionine and regenerating tetrahydrofolate. This reaction is crucial for both methionine metabolism and for maintaining the folate cycle needed for DNA synthesis. Adenosylcobalamin is a cofactor for the mitochondrial enzyme methylmalonyl-CoA mutase, which converts L-methylmalonyl-CoA to succinyl-CoA, an important step in the catabolism of odd-chain fatty acids and certain amino acids.
When vitamin B12 is deficient, both of these enzymatic pathways are impaired. The disruption of methionine synthase leads to accumulation of homocysteine and trapping of folate as 5-methyltetrahydrofolate (the so-called “methyl trap”), which in turn impairs DNA synthesis and results in megaloblastic changes in rapidly dividing cells, particularly in the bone marrow and gastrointestinal epithelium. The impairment of methylmalonyl-CoA mutase leads to accumulation of methylmalonic acid, which is believed to contribute to the characteristic neurological damage seen in vitamin B12 deficiency through disruption of myelin synthesis and maintenance.
Cyanocobalamin Farmacia is indicated for the treatment and prevention of vitamin B12 deficiency in the following clinical situations:
- Pernicious anemia: An autoimmune condition in which antibodies against intrinsic factor or gastric parietal cells impair the absorption of vitamin B12 from the gut. Despite the absence of intrinsic factor, high-dose oral cyanocobalamin (1 mg) achieves therapeutic B12 levels through passive diffusion, which absorbs approximately 1% of the oral dose independently of intrinsic factor.
- Megaloblastic anemia from B12 deficiency: Characterized by the production of abnormally large, immature red blood cells (megaloblasts) due to impaired DNA synthesis. Patients present with fatigue, weakness, pallor, and shortness of breath.
- Dietary deficiency: Occurring in strict vegans, vegetarians, and individuals with inadequate dietary intake. Since vitamin B12 is found naturally only in animal-derived foods, individuals following plant-based diets require supplementation.
- Malabsorption syndromes: Including conditions such as Crohn disease affecting the terminal ileum, celiac disease, small intestinal bacterial overgrowth, chronic atrophic gastritis, and following gastrointestinal surgery (gastrectomy or ileal resection).
- Drug-induced deficiency: Long-term use of metformin, proton pump inhibitors, and H2-receptor antagonists has been associated with reduced vitamin B12 absorption and clinical deficiency.
- Neurological manifestations of B12 deficiency: Including peripheral neuropathy, subacute combined degeneration of the spinal cord, cognitive impairment, and depression.
Vitamin B12 is listed on the WHO Model List of Essential Medicines, underscoring its critical importance in global health. The World Health Organization estimates that vitamin B12 deficiency affects 6–20% of the general population in developed countries and even higher proportions in populations with limited access to animal-derived foods. Early recognition and treatment of vitamin B12 deficiency is essential because neurological damage, while initially reversible, may become permanent if the deficiency is left untreated for prolonged periods.
A landmark Cochrane systematic review and multiple randomized controlled trials have demonstrated that high-dose oral cyanocobalamin (1000–2000 micrograms daily) is as effective as intramuscular injections for correcting vitamin B12 levels and improving symptoms in most patients. Oral therapy offers advantages including reduced cost, patient convenience, elimination of injection-related discomfort, and suitability for long-term maintenance. However, injectable B12 may be preferred when rapid correction is needed, in patients with severe neurological symptoms, or in cases of severe ileal disease.
What Should You Know Before Taking Cyanocobalamin Farmacia?
Before starting treatment with Cyanocobalamin Farmacia, it is important that your healthcare provider has confirmed vitamin B12 deficiency through appropriate laboratory testing. This typically includes measurement of serum vitamin B12 levels and, in cases where the diagnosis is uncertain, measurement of methylmalonic acid (MMA) and/or homocysteine levels, which are elevated in B12 deficiency. A complete blood count with peripheral blood smear may reveal megaloblastic changes indicative of B12-related anemia. Establishing the cause of the deficiency is also important, as it determines the duration of treatment and whether additional investigations are needed.
Contraindications
There are few absolute contraindications to cyanocobalamin therapy, but those that exist are important:
- Leber hereditary optic neuropathy (LHON): This is the most critical contraindication. Cyanocobalamin must not be used in patients with Leber hereditary optic neuropathy, a rare mitochondrial genetic condition. In these patients, cyanocobalamin can cause severe and rapid optic atrophy, potentially leading to sudden and permanent blindness. The cyanide moiety in cyanocobalamin is thought to further impair already compromised mitochondrial function in the optic nerve of LHON patients.
- Known hypersensitivity: Patients with a documented allergy to cyanocobalamin, hydroxocobalamin, cobalt, or any of the excipients in the tablet formulation should not take this medication.
If you have Leber hereditary optic neuropathy or a family history of this condition, do not take cyanocobalamin. The cyanide component can worsen optic nerve damage in this genetic condition. Consult your doctor about alternative forms of vitamin B12 such as hydroxocobalamin or methylcobalamin.
Warnings and Precautions
While cyanocobalamin is one of the safest medications available, several important clinical considerations apply:
- Masking of folate deficiency: Vitamin B12 supplementation can correct the hematological abnormalities (megaloblastic anemia) of folate deficiency without addressing the underlying folate deficiency itself. This is clinically significant because folate deficiency during pregnancy increases the risk of neural tube defects. Always ensure adequate folate status is also assessed when treating B12 deficiency.
- Hypokalemia risk: In patients with severe megaloblastic anemia, the rapid correction of B12 deficiency can lead to a sudden increase in red blood cell production (reticulocytosis), which may cause a temporary but clinically significant drop in serum potassium levels. In severe cases, this hypokalemia can cause cardiac arrhythmias. Potassium levels should be monitored during the initial weeks of treatment in patients with severe anemia.
- Polycythemia vera: Vitamin B12 should be used with caution in patients with polycythemia vera, as cobalamin is involved in erythropoiesis and supplementation could theoretically exacerbate the condition.
- Diagnostic interference: High-dose cyanocobalamin supplementation can interfere with certain laboratory assays. It can produce falsely normal serum B12 levels even if tissue-level deficiency persists. Methylmalonic acid and homocysteine levels are more reliable markers for assessing true B12 status during oral supplementation.
- Cobalt allergy: Cyanocobalamin contains cobalt as part of its molecular structure. Patients with known cobalt allergy should inform their healthcare provider, although clinically significant reactions from the trace amounts of cobalt in standard doses are extremely rare.
Pregnancy and Breastfeeding
Vitamin B12 is essential during pregnancy for normal fetal development, particularly for the formation of the neural tube and brain development. Adequate vitamin B12 levels during pregnancy reduce the risk of neural tube defects, low birth weight, and preterm delivery. Cyanocobalamin at therapeutic doses is considered safe during pregnancy and is categorized as safe for use by major regulatory authorities including the FDA and EMA.
Vitamin B12 is naturally present in breast milk, and maternal B12 levels directly influence the amount available to the nursing infant. Breastfeeding mothers who are B12 deficient (particularly vegans or those with pernicious anemia) should supplement to ensure adequate B12 transfer to the infant. Cyanocobalamin supplementation during breastfeeding is considered safe and is in fact recommended for mothers with known or suspected deficiency.
The WHO recommends that pregnant and breastfeeding women consume adequate vitamin B12 (2.6 micrograms and 2.8 micrograms daily, respectively) to support both maternal health and fetal/infant neurodevelopment. Higher therapeutic doses, such as the 1 mg provided by Cyanocobalamin Farmacia, are used when clinical deficiency is documented and are considered safe under medical supervision.
If you are pregnant, planning to become pregnant, or breastfeeding, inform your healthcare provider. While vitamin B12 supplementation is safe and often recommended during pregnancy and breastfeeding, the correct dose should be determined by your doctor based on your B12 levels and individual needs.
How Does Cyanocobalamin Farmacia Interact with Other Drugs?
Drug interactions with cyanocobalamin are primarily one-directional: certain medications reduce the absorption or effectiveness of vitamin B12, rather than cyanocobalamin affecting other drugs. Understanding these interactions is important for both preventing drug-induced B12 deficiency and ensuring optimal response to B12 supplementation. Unlike many other medications, cyanocobalamin does not undergo hepatic metabolism via cytochrome P450 enzymes and does not induce or inhibit these enzymes, resulting in a very favorable drug interaction profile.
Major Interactions
| Drug | Interaction | Clinical Significance | Management |
|---|---|---|---|
| Metformin | Reduces B12 absorption by up to 30% through calcium-dependent ileal membrane antagonism | Clinically significant B12 deficiency develops in 10–30% of long-term metformin users | Monitor B12 levels annually; supplement if deficient; consider calcium co-administration |
| Chloramphenicol | May reduce the hematological response to vitamin B12 by suppressing bone marrow red cell production | Can blunt the reticulocyte response and delay anemia correction | Monitor blood counts more frequently; consider alternative antibiotics if possible |
| Colchicine | Impairs intestinal absorption of vitamin B12 through disruption of ileal mucosal function | Significant at doses used for chronic gout therapy | Monitor B12 levels during chronic colchicine use; may require higher B12 doses |
Minor Interactions
| Drug | Interaction | Clinical Significance | Management |
|---|---|---|---|
| Proton pump inhibitors (PPIs) | Reduce gastric acid secretion, impairing release of protein-bound B12 from food; do not significantly affect absorption of supplemental crystalline cyanocobalamin | Risk increases with duration of PPI use (>2 years) | Monitor B12 levels in patients on long-term PPIs; supplemental B12 is well absorbed despite PPI use |
| H2-receptor antagonists | Similar mechanism to PPIs but with a lesser degree of acid suppression | Lower risk than PPIs; clinically relevant mainly with long-term use | Monitor B12 levels periodically with chronic use |
| Aminosalicylic acid | May reduce absorption of vitamin B12 from the gastrointestinal tract | Moderate; primarily relevant during tuberculosis treatment | Monitor B12 levels; supplement if deficient |
| Nitrous oxide | Irreversibly oxidizes the cobalt atom in vitamin B12, inactivating both methylcobalamin and adenosylcobalamin | Can precipitate acute neurological deterioration in patients with borderline or low B12 levels | Ensure adequate B12 status before elective surgery involving N2O anesthesia; avoid prolonged N2O exposure |
| Ascorbic acid (vitamin C) | Large doses of vitamin C may destroy vitamin B12 when taken simultaneously | Minimal at normal dietary intakes; potentially relevant at megadoses (>1 g) | Separate administration by at least 2 hours if taking high-dose vitamin C |
It is worth noting that cyanocobalamin does not have clinically significant pharmacokinetic interactions as a perpetrator. It is not metabolized by hepatic cytochrome P450 enzymes, does not affect drug transporters, and does not alter the absorption, distribution, metabolism, or elimination of other medications. This makes it exceptionally well-suited for use in patients on complex medication regimens, which is common in the elderly population where B12 deficiency is also most prevalent.
Chronic alcohol consumption can impair vitamin B12 absorption and liver storage. Patients with alcohol use disorder are at increased risk of B12 deficiency and may require higher doses or longer treatment duration. There are no direct pharmacological interactions between cyanocobalamin and alcohol.
What Is the Correct Dosage of Cyanocobalamin Farmacia?
The dosage of Cyanocobalamin Farmacia should be individualized based on the severity of deficiency, the underlying cause, and the patient’s clinical response. The following dosage recommendations are based on international guidelines from the British National Formulary (BNF), NICE, and established clinical practice. Always follow the specific dosage instructions provided by your healthcare provider, as individual requirements may vary.
Adults
Treatment of Confirmed B12 Deficiency
Dose: 1 mg (1000 micrograms) once daily
Duration: Initially daily for 4–12 weeks to replete body stores, then continued as maintenance therapy. For pernicious anemia and other irreversible causes, treatment is lifelong. For reversible causes (dietary deficiency), treatment may be continued for 3–6 months until levels normalize and the underlying cause is addressed.
Administration: Take the tablet with a glass of water. May be taken with or without food, though taking with a meal may improve tolerance.
Maintenance Therapy
Dose: 1 mg once daily or as directed by the prescribing physician
Duration: Lifelong for pernicious anemia, post-gastrectomy patients, and patients with irreversible malabsorption. Periodic reassessment for other causes.
Children
Pediatric Dosing
The use of Cyanocobalamin Farmacia 1 mg tablets in children has not been extensively studied. Vitamin B12 supplementation in children should be prescribed and supervised by a pediatric specialist. Dosing is generally based on age, weight, and severity of deficiency. For infants born to B12-deficient mothers, injectable B12 is usually the preferred initial treatment due to the urgency of correcting deficiency during critical neurodevelopmental periods.
Elderly
Geriatric Dosing
Dose: 1 mg once daily (same as adults)
No dose adjustment is required in elderly patients. In fact, elderly patients are one of the most common populations requiring B12 supplementation due to age-related atrophic gastritis, reduced gastric acid secretion, and higher prevalence of polypharmacy (including PPIs and metformin). The prevalence of B12 deficiency in adults over 60 years is estimated at 10–15% in developed countries. Oral high-dose cyanocobalamin is particularly advantageous in elderly patients as it avoids the need for regular injection visits.
Missed Dose
If you miss a dose of Cyanocobalamin Farmacia, take it as soon as you remember on the same day. If it is already close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. Because vitamin B12 is stored in the liver with a reserve of 1–5 mg (sufficient for several years of normal metabolic demand), missing an occasional dose is unlikely to have any clinical consequence. However, regular consistent dosing is recommended for optimal therapeutic response, particularly during the initial correction phase.
Overdose
Cyanocobalamin has an exceptionally wide margin of safety. Vitamin B12 is a water-soluble vitamin, and excess amounts are efficiently excreted by the kidneys in the urine. There are no well-documented cases of clinically significant toxicity from oral cyanocobalamin overdose in the medical literature. Doses many times higher than the recommended therapeutic dose have been used in clinical studies without serious adverse effects.
If a significant overdose is suspected, contact your local poison control center or emergency services as a precaution, although the risk of serious harm is extremely low. Some patients may notice that their urine turns a pink or reddish color after taking high doses of cyanocobalamin; this is harmless and simply reflects renal excretion of the excess vitamin.
Swallow the film-coated tablet whole with a glass of water. Do not crush, chew, or break the tablet. The tablet can be taken with or without food. Try to take it at the same time each day to establish a routine. If you have difficulty swallowing tablets, speak with your pharmacist about whether alternative formulations may be available.
What Are the Side Effects of Cyanocobalamin Farmacia?
Oral cyanocobalamin has an excellent safety profile that has been established over decades of clinical use. Unlike injectable vitamin B12, which can occasionally cause injection site reactions and has been associated with rare anaphylactoid reactions, oral cyanocobalamin carries an extremely low risk of adverse effects. The following side effect profile is based on post-marketing surveillance data, clinical trial reports, and pharmacovigilance databases compiled from international regulatory agencies.
It is important to understand that many of the symptoms experienced during the initial period of B12 supplementation may actually represent the body’s response to correction of the deficiency (such as the rapid increase in blood cell production) rather than true adverse drug reactions. Patients should report any unusual symptoms to their healthcare provider to distinguish between treatment effects and underlying disease symptoms.
Uncommon
May affect up to 1 in 100 people
- Nausea
- Diarrhea
- Headache
- Dizziness
- Mild skin itching (pruritus)
Rare
May affect up to 1 in 1,000 people
- Skin rash or urticaria (hives)
- Acne-like skin eruptions (acneiform dermatitis)
- Sensation of swelling of the entire body
- Peripheral vascular thrombosis
- Initial worsening of neurological symptoms (paradoxical exacerbation)
Very Rare / Not Known
Reported in isolated cases or frequency cannot be estimated
- Anaphylaxis or severe allergic reactions (extremely rare with oral administration)
- Hypokalemia during initial treatment of severe megaloblastic anemia
- Polycythemia (excessive red blood cell production, usually only with prolonged high-dose therapy)
- Optic atrophy in patients with Leber hereditary optic neuropathy
A notable clinical phenomenon observed during the early treatment of severe vitamin B12 deficiency is reticulocytosis, which typically peaks between days 5 and 8 of therapy. This represents a surge in red blood cell production by the bone marrow as it responds to the newly available vitamin B12. While this is a positive therapeutic response, the rapid production of new red blood cells can consume potassium, iron, and folate, potentially leading to temporary hypokalemia, iron deficiency, or unmasking of concurrent folate deficiency. Healthcare providers typically monitor electrolytes and blood counts during the first weeks of treatment in patients with severe anemia.
An unusual but well-documented phenomenon is the initial worsening of neurological symptoms (paradoxical exacerbation) that can occur during the first few days to weeks of B12 replacement therapy. This is thought to result from the remyelination process and nerve repair, and it typically resolves spontaneously as treatment continues. Patients should be informed about this possibility so they are not alarmed and do not discontinue treatment prematurely.
While serious side effects from oral cyanocobalamin are extremely rare, seek medical attention immediately if you experience signs of an allergic reaction such as difficulty breathing, swelling of the face, lips, tongue, or throat, or severe skin rash with blistering. Also contact your healthcare provider if you notice rapid heartbeat, chest pain, or significant worsening of neurological symptoms.
How Should You Store Cyanocobalamin Farmacia?
Proper storage of Cyanocobalamin Farmacia is important to maintain the potency and quality of the medication throughout its shelf life. Cyanocobalamin is relatively stable under normal storage conditions, but like all pharmaceutical products, it can degrade if exposed to excessive heat, light, or moisture.
Follow these storage guidelines to ensure your medication remains effective:
- Temperature: Store at room temperature, ideally below 25°C (77°F). Do not refrigerate or freeze the tablets. Avoid storing in locations subject to temperature extremes, such as near radiators, in direct sunlight, or in vehicles during summer.
- Light protection: Keep the tablets in their original packaging (blister packs or bottle) to protect from light. Cyanocobalamin is photosensitive and can degrade when exposed to prolonged direct light, converting to inactive forms.
- Moisture protection: Store in a dry place. Do not keep the medication in bathrooms or other humid environments, as moisture can affect the integrity of film-coated tablets.
- Child safety: Keep out of sight and reach of children. While cyanocobalamin has very low toxicity, all medications should be stored safely away from children.
- Expiration date: Do not use the medication after the expiry date (EXP) stated on the packaging. The expiry date refers to the last day of that month.
- Disposal: Do not dispose of unused medication via household waste or wastewater. Return any unused or expired tablets to your pharmacy for proper disposal according to local regulations.
If you notice any change in the appearance of the tablets (such as discoloration, crumbling, or an unusual odor), do not take them. Contact your pharmacist for advice and bring the affected medication for inspection and proper disposal.
What Does Cyanocobalamin Farmacia Contain?
Understanding the complete composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical excipients. Cyanocobalamin Farmacia is formulated as a film-coated tablet to protect the active ingredient from degradation and to facilitate swallowing.
Active Ingredient
Each film-coated tablet contains 1 mg (1000 micrograms) of cyanocobalamin. Cyanocobalamin (chemical formula: C63H88CoN14O14P, molecular weight: 1355.37 g/mol) is a synthetic organometallic compound with a deep red color. It consists of a corrin ring system coordinated to a central cobalt atom, with a cyanide group as one of the axial ligands. The corrin ring is structurally similar to the porphyrin ring found in hemoglobin but differs in having a direct carbon-carbon bond between two of the pyrrole rings rather than a bridging methine group.
Inactive Ingredients (Excipients)
The film-coated tablet typically contains excipients such as:
- Tablet core: Lactose monohydrate (or other filler/diluent), microcrystalline cellulose, croscarmellose sodium (disintegrant), magnesium stearate (lubricant), povidone (binder)
- Film coating: Hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E171), macrogol/polyethylene glycol, iron oxide pigments (for coloring)
The exact excipient composition may vary by manufacturer and batch. For a complete and current list of excipients, refer to the patient information leaflet included with your specific product, or consult your pharmacist. Patients with lactose intolerance should note that the tablet may contain lactose monohydrate; however, the amount per tablet is typically very small (usually less than 100 mg) and is well tolerated by most patients with lactose intolerance.
Cyanocobalamin Farmacia 1 mg tablets are film-coated and may appear pink, red, or dark red due to the natural color of cyanocobalamin (vitamin B12 has a characteristic deep red color). The tablet is round and designed for oral administration. Swallow whole; do not crush or chew.
Frequently Asked Questions About Cyanocobalamin Farmacia
Cyanocobalamin Farmacia is a prescription-strength vitamin B12 supplement used to treat and prevent vitamin B12 deficiency. It is commonly prescribed for pernicious anemia, megaloblastic anemia due to B12 deficiency, dietary deficiency in vegans and vegetarians, malabsorption conditions (such as Crohn disease, celiac disease, or post-gastric surgery), drug-induced B12 deficiency (from metformin, proton pump inhibitors), and neurological symptoms associated with low vitamin B12 levels such as peripheral neuropathy and cognitive impairment.
Yes, multiple systematic reviews including a Cochrane review have demonstrated that high-dose oral cyanocobalamin (1000–2000 micrograms daily) is as effective as intramuscular injections for correcting vitamin B12 deficiency in most patients. Even in patients with pernicious anemia who lack intrinsic factor, approximately 1% of high oral doses is absorbed through passive diffusion, which provides adequate therapeutic levels at the 1 mg dose. However, injectable B12 may be preferred in cases requiring rapid correction, severe neurological symptoms, or severe ileal malabsorption.
Treatment duration depends on the underlying cause of your B12 deficiency. For pernicious anemia and other irreversible causes of malabsorption (such as after gastrectomy or ileal resection), treatment is lifelong. For reversible causes such as dietary deficiency in vegans, treatment typically continues for 3–6 months to replete body stores, followed by ongoing dietary supplementation. For drug-induced deficiency, treatment may be needed as long as the causative medication is continued. Your doctor will advise on the appropriate duration based on your specific situation and laboratory monitoring results.
Cyanocobalamin itself is a synthetic compound produced through bacterial fermentation and is not derived from animal sources, making the active ingredient suitable for vegans. However, the film-coated tablet may contain excipients such as lactose monohydrate, which is derived from milk. Vegans should check the full excipient list with their pharmacist. Vitamin B12 supplementation is essential for vegans since B12 is naturally found only in animal-derived foods, and the body’s B12 stores can take several years to become depleted, meaning deficiency may develop insidiously.
Vitamin B12 deficiency can present with a wide range of symptoms affecting multiple organ systems. Hematological signs include megaloblastic anemia causing fatigue, weakness, pallor, shortness of breath, and heart palpitations. Neurological symptoms include peripheral neuropathy (tingling and numbness in hands and feet), difficulty walking, balance problems, muscle weakness, and in severe cases, subacute combined degeneration of the spinal cord. Cognitive and psychiatric symptoms include memory difficulties, confusion, depression, irritability, and even psychosis in severe cases. Oral manifestations include glossitis (swollen, painful tongue), mouth ulcers, and angular cheilitis. Gastrointestinal symptoms may include loss of appetite, weight loss, and diarrhea or constipation.
Yes, and in fact it is often recommended. Metformin is well known to reduce vitamin B12 absorption, with clinically significant deficiency developing in 10–30% of long-term users. Taking Cyanocobalamin Farmacia alongside metformin is a recognized approach to preventing or treating this drug-induced deficiency. The two medications can be taken at the same time or at different times of day; there is no specific timing requirement. International diabetes guidelines recommend routine monitoring of B12 levels in all patients on long-term metformin therapy.
References
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023. Cyanocobalamin listed as an essential medicine for the treatment of vitamin deficiencies.
- Vidal-Alaball J, Butler CC, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database of Systematic Reviews. 2005;(3):CD004655. Updated 2018. doi:10.1002/14651858.CD004655.pub2
- National Institute for Health and Care Excellence (NICE). Clinical Knowledge Summaries: Anaemia – B12 and folate deficiency. NICE; 2024. Clinical guidelines for diagnosis and management of vitamin B12 deficiency.
- British National Formulary (BNF). Cyanocobalamin. London: BMJ Group and Pharmaceutical Press; 2025. Prescribing information, dosage recommendations, and interactions.
- Stabler SP. Vitamin B12 Deficiency. New England Journal of Medicine. 2013;368(2):149-160. doi:10.1056/NEJMcp1113996
- Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B12 deficiency. Nature Reviews Disease Primers. 2017;3:17040. doi:10.1038/nrdp.2017.40
- Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology & Metabolism. 2016;101(4):1754-1761. doi:10.1210/jc.2015-3754
- European Medicines Agency (EMA). Assessment of cyanocobalamin-containing medicinal products. EMA/CHMP; 2023.
- Langan RC, Goodbred AJ. Vitamin B12 Deficiency: Recognition and Management. American Family Physician. 2017;96(6):384-389.
- Devalia V, Hamilton MS, Molloy AM; British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. British Journal of Haematology. 2014;166(4):496-513. doi:10.1111/bjh.12959
Medical Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Hematology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent review according to WHO, NICE, BNF, and EMA guidelines
Evidence Framework
GRADE methodology – Systematic evaluation of evidence quality for all medical claims
Independence
No pharmaceutical funding – All content is editorially independent with no commercial influence
All medical information on iMedic is reviewed by qualified healthcare professionals and updated regularly to reflect current evidence-based guidelines. Last reviewed: .